These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18072266)

  • 21. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A; Feely J
    Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats.
    Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
    Hypertens Res; 2014 Mar; 37(3):194-201. PubMed ID: 24132009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPLC enantiomeric resolution of nebivolol on normal and reversed amylose based chiral phases.
    Aboul-Enein HY; Ali I
    Pharmazie; 2001 Mar; 56(3):214-6. PubMed ID: 11265585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta.
    Tran Quang T; Rozec B; Audigane L; Gauthier C
    Br J Pharmacol; 2009 Feb; 156(4):601-8. PubMed ID: 19210511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium.
    Bundkirchen A; Nguyen Q; Brixius K; Bölck B; Mehlhorn U; Schwinger RH
    Eur J Pharmacol; 2003 Aug; 476(1-2):97-105. PubMed ID: 12969754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human beta 1- and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known beta-adrenergic blockers.
    Pauwels PJ; Van Gompel P; Leysen JE
    Biochem Pharmacol; 1991 Oct; 42(9):1683-9. PubMed ID: 1681809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat.
    Schneider J; Fruh C; Wilffert B; Peters T
    Pharmacology; 1990; 40(1):33-41. PubMed ID: 1970437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular effects of intracerebroventricular injections of (+/-)-nebivolol and its enantiomers--a comparison with those of metoprolol in the rat.
    Midol-Monnet M; Davy M; Heimburger M; Beslot F; Cohen Y
    J Pharm Pharmacol; 1991 Jul; 43(7):504-9. PubMed ID: 1682465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum.
    Reidenbach C; Schwinger RH; Steinritz D; Kehe K; Thiermann H; Klotz T; Sommer F; Bloch W; Brixius K
    Life Sci; 2007 Jun; 80(26):2421-7. PubMed ID: 17512554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of nebivolol.
    Mangrella M; Rossi F; Fici F; Rossi F
    Pharmacol Res; 1998 Dec; 38(6):419-31. PubMed ID: 9990650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
    Cheymol G; Poirier JM; Carrupt PA; Testa B; Weissenburger J; Levron JC; Snoeck E
    Br J Clin Pharmacol; 1997 Jun; 43(6):563-70. PubMed ID: 9205815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.
    Van de Water A; Xhonneux R; Reneman RS; Janssen PA
    Eur J Pharmacol; 1988 Oct; 156(1):95-103. PubMed ID: 3208842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer.
    Xhonneux R; Wouters L; Reneman RS; Janssen PA
    Eur J Pharmacol; 1990 Jun; 181(3):261-5. PubMed ID: 1974517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment.
    Wolf SC; Sauter G; Jobst J; Kempf VA; Risler T; Brehm BR
    Int J Cardiol; 2008 Mar; 125(1):4-10. PubMed ID: 17467819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of nebivolol stereoisomers on the action of adrenaline on blood pressure, heart rate and blood levels of noradrenaline and DOPEG.
    Borges N; Martel F; Branco D; Osswald W
    J Auton Pharmacol; 1992 Dec; 12(6):429-35. PubMed ID: 1361931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nebivolol: new therapy update.
    Sule SS; Frishman W
    Cardiol Rev; 2006; 14(5):259-64. PubMed ID: 16924166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of nitric oxide release by nebivolol and its metabolites.
    Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
    Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.